Cost-Effectiveness of Hepatitis C Virus (HCV) Treatment with Telaprevir/Pegylated Interferon Alpha/Ribavirin Triple Therapy Versus Waiting for New Regimens in France
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.1116
https://www.valueinhealthjournal.com/article/S1098-3015(13)03021-0/fulltext
Title :
Cost-Effectiveness of Hepatitis C Virus (HCV) Treatment with Telaprevir/Pegylated Interferon Alpha/Ribavirin Triple Therapy Versus Waiting for New Regimens in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03021-0&doi=10.1016/j.jval.2013.08.1116
First page :
A497
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
970